The study found that the use of anti-CXCR3 monoclonal antibodies significantly reduced T cell migration and alleviated the severity of arthritis, including reductions in clinical symptoms, weight loss, and neutrophil accumulation in the joints. This evidence concerns the gene CXCR3 and Arthritis.